Evidence supporting the use of: Immunoglobulin G
For the health condition: Lymphoma

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Immunoglobulin G (IgG), often administered as intravenous immunoglobulin (IVIG), is used in the supportive management of certain patients with lymphoma, particularly those who develop secondary hypogammaglobulinemia and recurrent infections due to either the disease itself or its treatment (e.g., chemotherapy, rituximab). The primary rationale is not a direct antitumor effect, but rather to replace deficient antibodies and reduce the risk of serious infections in immunocompromised individuals. Several clinical guidelines, including those from the American Society of Hematology and the British Society for Haematology, recommend consideration of IVIG in lymphoma patients experiencing severe, recurrent infections with documented hypogammaglobulinemia. Evidence supporting its use is mostly from observational studies and a few randomized controlled trials, which show reductions in infection rates but not in overall survival. Thus, while the use of IgG is supported by scientific evidence for infection prevention in select lymphoma patients, it is not used as a direct treatment for lymphoma itself. Routine use in all lymphoma patients is not recommended, and therapy is typically reserved for those with frequent or severe infections and confirmed antibody deficiency.

More about Immunoglobulin G
More about Lymphoma

Products containing Immunoglobulin G

We currently have no products on Vitabase that contain this ingredient.